May 16-19, 2004, Crystal Gateway Marriott,
Arlington, VA
PROGRAM:
MONDAY, MAY 17TH
8:00AM-8:30AM
WELCOME
& INTRODUCTION Mark Sculpher, MSc, PhD,
Professor, University of York, Centre for Health Economics, Heslington York
In Memoriam: Bernie O'Brien PhD
Presented by: Michael Drummond PhD,
Professor of Economics and Director, Centre for Health Economics, University
of York, Heslington, York
PRESIDENTIAL ADDRESS Sean Sullivan PhD,
2003-2004 ISPOR President & Professor, University of Washington, Seattle,
WA, USA
8:30AM-9:45AM
FIRST PLENARY
SESSION
MEDICARE
DRUG BENEFIT & COST-EFFECTIVENESS: WHO PLAYS & WHO PAYS
Moderator:Bryan Luce PhD MBA,
Chairman of the Board, MEDTAP International, Bethesda, MD, USA
Speakers:
Sean Tunis MD, MSc, Chief Medical Officer
of CMS & Director, Office of Clinical Standards & Quality, Coverage and
Analysis Group, Centers for Medicare and Medicaid Services, Baltimore, MD,
USA; Jean Slutsky PA, MSPH, Acting
Director, Center for Outcomes and Evidence, Agency for Healthcare Research
and Quality (AHRQ), Rockville, MD, USA
This plenary session will address US legislation concerning Medicare Drug
Benefit Plan and the use of cost-effectiveness and outcomes research
information in drug selection decisions. The role of the Agency for Health
Care Research and Quality and the National Institutes of Health, as well as
the Food and Drug Administration in providing and regulating this
information will be discussed.
9:45AM-10:15AM
EXHIBITS & CONTRIBUTED POSTER PRESENTATIONS
VIEWING – SESSION I
10:15AM-11:15AM
CONTRIBUTED
PODIUM PRESENTATIONS – SESSION I
Pharmacoeconomics/health
economic, quality-of-life, and outcomes research study results for the
following diseases will be presented:
Cardiovascular Disease
CV1
HEALTH PREFERENCES AFTER CABG OR PCI FOLLOWING AN
ACUTE MYOCARDIAL INFARCTION Radeva J, Reed S, Weinfurt K, Anstrom K, Velazquez E, Schulman K
Duke Clinical Research Institute, Durham, NC, USA
CV2
CARDIOVASCULAR RISK OF SELECTIVE CYCLOOXYGENASE-2
INHIBITORS COMPARED TO OTHER NONSTEROIDAL ANTI-INFLAMMATORY AGENTS: AN
OBSERVATIONAL STUDY OF A MEDICAID POPULATION Shaya FT, Blume SW, Blanchette CM, Mullins CD, Weir MR
University of Maryland, Baltimore, MD, USA
CV3
THE USE OF A PROBABILISTIC DECISION MODEL TO
ASSESS THE COST-EFFECTIVENESS OF DRUG-ELUTING STENTS IN ALTERNATIVE
PATIENT SUB-GROUPS
Sculpher M, Hawkins NS1 1University of York, York, United Kingdom
CV4
LOWER CARDIOVASCULAR RISK ASSOCIATED WITH
PIOGLITAZONE MONOTHERAPY COMPARED TO INSULIN MONOTHERAPY: A
RETROSPECTIVE PROPENSITY SCORE MATCHED COHORT STUDY
Iyer S1, Xu Y1, Rosenson R2,
Rajagopalan R1 1Takeda Pharmaceuticals North America Inc, Lincolnshire, IL,
USA; 2Northwestern University, Feinberg School of Medicine,
Chicago, IL, USA
Cancer
CN1
THE STATE OF THE SCIENCE OF HRQOL ASSESSMENT IN
CANCER: FINDINGS FROM THE CANCER OUTCOMES MEASUREMENT WORKING GROUP
Lipscomb J1, Gotay C2, Snyder C1 1National Cancer Institute, Bethesda, MD, USA; 2Cancer
Research Center of Hawaii, Honolulu, HI, USA
CN2
COST-EFFECTIVENESS OF DIAGNOSTIC, STAGING, AND
TREATMENT OPTIONS FOR MELANOMA Chavez YE1, Lee WC2, Botteman MF3,
Pashos CL4 1Abt Associates, Inc, Bethesda, MD, USA; 2Abt
Associates Inc. - HERQuLES, Bethesda, MD, USA; 3Abt
Associates Inc. - HERQuLES, Cambridge, MA, USA; 4Abt
Associates Inc, Cambridge, MA, USA
CN3
COST-EFFECTIVENESS OF ANASTROZOLE VS TAMOXIFEN AS
ADJUVANT THERAPY IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER (EBC):
A UK NATIONAL HEALTH SERVICE (NHS) PERSPECTIVE Benedict Á1, Mansel on behalf of the ATAC Trialists'
Group R2 1MEDTAP International Inc, London, United Kingdom; 2University
of Wales College of Medicine, Cardiff, United Kingdom
CN4
COST-EFFECTIVENESS (CE) ANALYSIS OF
INTERFERON-ALPHA IN HIGH-RISK MELANOMA PATIENTS Ding M1, Xing Y2, Shih T2, Cox D1,
Cantor S2, Cormier J2 1Rice University, Houston, TX, USA; 2The
University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
Respiratory Disorders and Infections
RI1
THE EFFECT OF PRESCRIPTION DRUG COVERAGE ON THE
COST OF CARE FOR MEDICARE BENEFICIARIES WITH ASTHMA Atherly A, Williams S, Redd S
Centers for Disease Control, Atlanta, GA, USA
RI2 THE EXCESS COST OF
CHRONIC OBSTRUCTIVE PULMONARY DISEASE FROM A MANAGED-CARE PERSPECTIVE
Boulanger L1, Marton JP2, Friedman M1,
Dixon D1, Menzin J1 1Boston Health Economics, Inc, Waltham, MA, USA; 2Pfizer
US Outcomes Research Group, New York, NY, USA
RI3
COST-EFFECTIVENESS OF INFLUENZA VACCINE IN 6-24
MONTH OLD CHILDREN Woolcott JC1, Marra F1, Brunham RC2 1BC Centre for Disease Control, Vancouver, BC, Canada; 2University
of British Columbia Centre for Disease Control, Vancouver, BC, Canada
RI4
AN ECONOMIC ANALYSIS OF RAPID TESTS AND ANTIVIRAL
TREATMENTS FOR INFLUENZA IN CHILDREN Prosser LA1, Uyeki TM2, Bridges CB2,
Rego VH1, Meltzer M2, Schwartz B2,
Thompson WW2, Fukuda K2, Lieu TA1 1Harvard Medical School and Harvard Pilgrim Health Care,
Boston, MA, USA; 2CDC, Atlanta, GA, USA
Arthritis
AR1
ASSESSING THE COST-EFFECTIVENESS OF COX-2 SPECIFIC
INHIBITORS FOR ARTHRITIS IN THE VETERANS HEALTH ADMINISTRATION
Schaefer M1, DeLattre M1, Gao X2,
Stephens J2, Botteman M2, Morreale A1 1VA San Diego Health care System, San Diego, CA, USA; 2Abt
Associates Clinical Trials, Bethesda, MD, USA
AR2
A COST-EFFECTIVENESS ANALYSIS OF BIOLOGICAL
TREATMENTS FOR RHEUMATOID ARTHRITIS Chiou CF1, Wanke L2, Yu E2,
Ofman J2 1Zynx Health, A Cerner Company, Beverly Hills, CA, USA;
2Amgen, Inc, Thousand Oaks, CA, USA
AR3
REVALIDATION OF THE ORIGINAL CEDARS-SINAI
RHEUMATOID ARTHRITIS HEALTH-RELATED QUALITY OF LIFE (CSHQ-RA) INSTRUMENT Chiou CF1, Sherbourne C2, Cornelio IL3,
Lubeck D3, Paulus H4, Dylan M1, Weisman
M5 1Zynx Health, A Cerner Company, Beverly Hills, CA, USA;
2RAND Corporation, Santa Monica, CA, USA; 3Amgen, Inc,
Thousand Oaks, CA, USA; 4UCLA, Los Angeles, CA, USA; 5Cedars-Sinai
Health System, Los Angeles, CA, USA
AR4
THE DEVELOPMENT OF PROPENSITY SCORES FROM
ADMINISTRATIVE DATABASES FOR THE ANALYSIS OF THE EFFECTIVENESS OF AN
OSTEOARTHRITIS ACADEMIC DETAILING SERVICE ON PRESCRIBING BEHAVIOUR Graham SD, Hartzema AG
University of Florida, Gainesville, FL, USA
MODERATOR: Jean Paul Gagnon PhD,
Director Public Policy, Aventis Pharmaceuticals Inc., Bridgewater, NJ, USA PANELISTS: Jean R. Slutsky, PA, MSPH,
Acting Director, Center for Outcomes and Evidence, Agency for Healthcare
Research and Quality (AHRQ), Rockville, MD, USA,
Kathleen Lohr PhD, Co-Director, RTI-UNC Evidence-based Practice
Center, Research Triangle Park, NC, USA; John Santa
MD, Former Administrator, Office of Oregon Health Policy and
Research, Portland, OR, USA
MODERATOR: Henry Glick PhD, Health
Economist, University of Pennsylvania, Division of Internal Medicine,
Philadelphia, PA, USA
PANELISTS:
Jeffrey Hoch PhD,
Assistant Professor, University of Western Ontario, Department of
Epidemiology and Biostatistics, London, ON, Canada;Andrew Willan PhD, Professor, Department of Public Health
Sciences, University of Toronto, Toronto, ON, Canada;
Joseph Heyse PhD, Executive Director, Merck
Research Laboratories, Biostatistics and Research Data Systems, West Point,
PA, USA; John Cook PhD, Health Economics, Merck
Research Laboratories, Blue Bell, PA, USA
MODERATOR: Charles Petrie PhD, Sr.
Director/Team Leader, Outcomes Research Group, Pfizer Inc, Groton, CT, USA;
PANELISTS: Adrian Towse MA, Director,
Office of Health Economics, London, UK;
Maureen Mangotich MD, MPH, Medical Director,
State Initiatives, Pfizer Health Solutions, Santa Monica, CA
MODERATORS: Teresa Kauf PhD,
Research Assistant Professor, Center
for Clinical and Genetic Economics, Duke Clinical Research Institute,
Durham, NC, USA
PANELISTS: Gerry Oster PhD, Vice
President, PAI, Brookline, MA, USA; Daniel Polsky PhD,
Research Associate Professor, General Internal Medicine, University of
Pennsylvania, Philadelphia, PA, USA
• Student Forum
• Compliance Special Interest Group Forum
Quality of Life Special
Interest Group Forum
4:30PM-4:35PM
Emerging Issues in PRO
Research: This session will examine major applied research issues that
are important for the development and use QoL and patient reported outcome
(PRO) measures. The discussion will identify other areas that might also be
added to a PRO/QoL research agenda and begin a dialog concerning ISPOR’s
role in furthering advances in applied PRO research.
Moderator:Pennifer Erickson PhD,
Co-founder, O.L.G.A., State College, PA, USA
4:35PM -4:50PM
Instrument Development and
Validation: How Much is Enough?
Speaker:Margaret Rothman PhD,
Executive Director, HE&P, PGSM, Johnson & Johnson Pharmaceutical Services,
LLC, Raritan, NJ, USA
4:50PM -5:05PM
The MCID and PRO Research:
Should We Draw a Line in the Sand?
Speaker: Nancy Kline Leidy PhD, President and CEO, MEDTAP International,
Bethesda, MD, USA
5:05PM -5:15PM
Discussion of Current Research
Issues: What’s Hot? What’s Not? Speaker: Pennifer Erickson PhD, Co-founder, O.L.G.A., State College, PA, USA
5:15PM
-5:30PM
Discussion
5:30PM-6:30PM
ISPOR Medication Compliance SIG Open Meeting
ISPOR Clinical Practice SIG Open Meeting
ISPOR Annual
Business Meeting
6:00PM-8:00PMM
EXHIBITORS’
OPEN HOUSE RECEPTION & CONTRIBUTED POSTER PRESENTATION –
SESSION I
